论文部分内容阅读
Ａｐｏｔｅｘ/Ｃａｎｇｅｎｅ两公司开发的口服铁螯合物ｄｅｆｅｒｉｐｒｏｎｅ(Ｄｅｆｅｒｏｍ/Ｆｅｒｒｉｐｒｏｘ)已获欧盟批准用于对ｄｅｆｅｒｏｘａｍｉｎｅ治疗禁忌的重症地中海贫血患者因需经常输血所致铁过量的治疗 ,这是该产品首次获准上市。重症地中海贫血是血红蛋
The oral ferric chelate deferiprone (Deferom / Ferriprox) developed by Apotex / Cangene has been approved by the European Union for the first time that this product is approved by the European Union for the treatment of iron overload in critically ill patients with thalassemia who are contraindicated with deferoxamine due to frequent blood transfusions Listing. Severe thalassemia is hemoglobin